Dual Roles of PARP-1 Promote Cancer Growth and Progression

被引:354
作者
Schiewer, Matthew J. [1 ,7 ]
Goodwin, Jonathan F. [1 ,7 ]
Han, Sumin
Brenner, J. Chad [8 ,9 ,12 ]
Augello, Michael A. [1 ,7 ]
Dean, Jeffry L. [1 ,7 ]
Liu, Fengzhi [2 ,7 ]
Planck, Jamie L. [3 ,7 ]
Ravindranathan, Preethi [15 ]
Chinnaiyan, Arul M. [8 ,9 ,10 ,11 ,12 ,14 ]
McCue, Peter [6 ,7 ]
Gomella, Leonard G. [4 ,7 ]
Raj, Ganesh V. [15 ]
Dicker, Adam P. [5 ,7 ]
Brody, Jonathan R. [2 ,7 ]
Pascal, John M. [3 ,7 ]
Centenera, Margaret M. [16 ,17 ]
Butler, Lisa M. [16 ,17 ]
Tilley, Wayne D. [16 ,17 ]
Feng, Felix Y. [8 ,11 ,13 ]
Knudsen, Karen E. [1 ,4 ,5 ,7 ]
机构
[1] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA
[4] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA
[5] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[6] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA
[7] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[8] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA
[9] Univ Michigan, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA
[10] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA
[11] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[12] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[13] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[14] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA
[15] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[16] Univ Adelaide, Sch Med, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia
[17] Hanson Inst, Adelaide, SA, Australia
基金
英国医学研究理事会;
关键词
POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; ADP-RIBOSE POLYMERASE; PROSTATE-CANCER; CHROMATIN-STRUCTURE; DNA; TRANSCRIPTION; BINDING; MODULATION; ABT-888; PROTEIN;
D O I
10.1158/2159-8290.CD-12-0120
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PARP-1 is an abundant nuclear enzyme that modifies substrates by poly(ADP-ribose)-ylation. PARP-1 has well-described functions in DNA damage repair and also functions as a context-specific regulator of transcription factors. With multiple models, data show that PARP-1 elicits protumorigenic effects in androgen receptor (AR)-positive prostate cancer cells, in both the presence and absence of genotoxic insult. Mechanistically, PARP-1 is recruited to sites of AR function, therein promoting AR occupancy and AR function. It was further confirmed in genetically defined systems that PARP-1 supports AR transcriptional function, and that in models of advanced prostate cancer, PARP-1 enzymatic activity is enhanced, further linking PARP-1 to AR activity and disease progression. In vivo analyses show that PARP-1 activity is required for AR function in xenograft tumors, as well as tumor cell growth in vivo and generation and maintenance of castration resistance. Finally, in a novel explant system of primary human tumors, targeting PARP-1 potently suppresses tumor cell proliferation. Collectively, these studies identify novel functions of PARP-1 in promoting disease progression, and ultimately suggest that the dual functions of PARP-1 can be targeted in human prostate cancer to suppress tumor growth and progression to castration resistance. SIGNIFICANCE: These studies introduce a paradigm shift with regard to PARP-1 function in human malignancy, and suggest that the dual functions of PARP-1 in DNA damage repair and transcription factor regulation can be leveraged to suppress pathways critical for promalignant phenotypes in prostate cancer cells by modulation of the DNA damage response and hormone signaling pathways. The combined studies highlight the importance of dual PARP-1 function in malignancy and provide the basis for therapeutic targeting. Cancer Discov; 2(12); 1134-49. (C) 2012 AACR.
引用
收藏
页码:1134 / 1149
页数:16
相关论文
共 63 条
[1]   Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].
Audeh, M. William ;
Carmichael, James ;
Penson, Richard T. ;
Friedlander, Michael ;
Powell, Bethan ;
Bell-McGuinn, Katherine M. ;
Scott, Clare ;
Weitzel, Jeffrey N. ;
Oaknin, Ana ;
Loman, Niklas ;
Lu, Karen ;
Schmutzler, Rita K. ;
Matulonis, Ursula ;
Wickens, Mark ;
Tutt, Andrew .
LANCET, 2010, 376 (9737) :245-251
[2]  
BENJAMIN RC, 1980, J BIOL CHEM, V255, P493
[3]   Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells [J].
Berger, R ;
Febbo, PG ;
Majumder, PK ;
Zhao, JJ ;
Mukherjee, S ;
Signoretti, S ;
Campbell, KT ;
Sellers, WR ;
Roberts, TM ;
Loda, M ;
Golub, TR ;
Hahn, WC .
CANCER RESEARCH, 2004, 64 (24) :8867-8875
[4]   A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes [J].
Boehm, M. ;
Locke, W. J. ;
Sutherland, R. L. ;
Kench, J. G. ;
Henshall, S. M. .
ONCOGENE, 2009, 28 (43) :3847-3856
[5]   PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma [J].
Brenner, J. Chad ;
Feng, Felix Y. ;
Han, Sumin ;
Patel, Sonam ;
Goyal, Siddharth V. ;
Bou-Maroun, Laura M. ;
Liu, Meilan ;
Lonigro, Robert ;
Prensner, John R. ;
Tomlins, Scott A. ;
Chinnaiyan, Arul M. .
CANCER RESEARCH, 2012, 72 (07) :1608-1613
[6]  
Brenner JC, 1999, CANCER CELL, V19, P664
[7]   Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation [J].
Burd, CJ ;
Petre, CE ;
Morey, LM ;
Wang, Y ;
Revelo, MP ;
Haiman, CA ;
Lu, S ;
Fenoglio-Preiser, CM ;
Li, JW ;
Knudsen, ES ;
Wong, JM ;
Knudsen, KE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2190-2195
[8]   Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors [J].
Centenera, Margaret M. ;
Gillis, Joanna L. ;
Hanson, Adrienne R. ;
Jindal, Shalini ;
Taylor, Renea A. ;
Risbridger, Gail P. ;
Sutherland, Peter D. ;
Scher, Howard I. ;
Raj, Ganesh V. ;
Knudsen, Karen E. ;
Tilley, Wayne D. ;
Butler, Lisa M. .
CLINICAL CANCER RESEARCH, 2012, 18 (13) :3562-3570
[9]   Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions [J].
D'Amours, D ;
Desnoyers, S ;
D'Silva, I ;
Poirier, GG .
BIOCHEMICAL JOURNAL, 1999, 342 :249-268
[10]   Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors [J].
Dean, Jeffry L. ;
McClendon, A. Kathleen ;
Hickey, Theresa E. ;
Butler, Lisa M. ;
Tilley, Wayne D. ;
Witkiewicz, Agnieszka K. ;
Knudsen, Erik S. .
CELL CYCLE, 2012, 11 (14) :2756-2761